Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI112899

Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans.

M M Levine, D Herrington, J R Murphy, J G Morris, G Losonsky, B Tall, A A Lindberg, S Svenson, S Baqar, and M F Edwards

Find articles by Levine, M. in: PubMed | Google Scholar

Find articles by Herrington, D. in: PubMed | Google Scholar

Find articles by Murphy, J. in: PubMed | Google Scholar

Find articles by Morris, J. in: PubMed | Google Scholar

Find articles by Losonsky, G. in: PubMed | Google Scholar

Find articles by Tall, B. in: PubMed | Google Scholar

Find articles by Lindberg, A. in: PubMed | Google Scholar

Find articles by Svenson, S. in: PubMed | Google Scholar

Find articles by Baqar, S. in: PubMed | Google Scholar

Find articles by Edwards, M. in: PubMed | Google Scholar

Published March 1, 1987 - More info

Published in Volume 79, Issue 3 on March 1, 1987
J Clin Invest. 1987;79(3):888–902. https://doi.org/10.1172/JCI112899.
© 1987 The American Society for Clinical Investigation
Published March 1, 1987 - Version history
View PDF
Abstract

Two Salmonella typhi mutants, 541Ty (Vi+) and 543Ty (Vi-), auxotrophic for p-aminobenzoate and adenine, were evaluated as live oral vaccines. 33 volunteers ingested single doses of 10(8), 10(9), or 10(10) vaccine organisms, while four others received two 2 X 10(9) organism doses 4 d apart. No adverse reactions were observed. Vaccine was recovered from coprocultures of 29 of 37 vaccinees (78%) and from duodenal string cultures of two; repeated blood cultures were negative. The humoral antibody response to S. typhi O, H, Vi, and lysate antigens in serum and intestinal fluid was meager. In contrast, all vaccinees manifested cell-mediated immune responses. After vaccination, 69% of vaccinees overall and 89% of recipients of doses greater than or equal to 10(9) responded to S. typhi particulate or purified O polysaccharide antigens in lymphocyte replication studies but not to antigens of other Salmonella or Escherichia coli. All individuals, postvaccination, demonstrated a significant plasma-dependent mononuclear cell inhibition of wild S. typhi.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 888
page 888
icon of scanned page 889
page 889
icon of scanned page 890
page 890
icon of scanned page 891
page 891
icon of scanned page 892
page 892
icon of scanned page 893
page 893
icon of scanned page 894
page 894
icon of scanned page 895
page 895
icon of scanned page 896
page 896
icon of scanned page 897
page 897
icon of scanned page 898
page 898
icon of scanned page 899
page 899
icon of scanned page 900
page 900
icon of scanned page 901
page 901
icon of scanned page 902
page 902
Version history
  • Version 1 (March 1, 1987): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts